Akari Therapeutics Plc Stock Analysis
| AKTX Stock | USD 1.21 0.09 8.04% |
Akari Therapeutics PLC is undervalued with Real Value of 14.65 and Target Price of 55.0. The main objective of Akari Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Akari Therapeutics PLC is worth, separate from its market price. There are two main types of Akari Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Akari Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Akari Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Akari Stock trading window is adjusted to America/New York timezone.
Akari |
Akari Stock Analysis Notes
The company recorded a loss per share of 2.58. Akari Therapeutics PLC had not issued any dividends in recent years. The entity had 1:20 split on the 17th of August 2023. Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Akari Therapeutics, Plc is based in London, the United Kingdom. Akari Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Akari Therapeutics PLC please contact Samir MD at 929 274 7510 or go to https://www.akaritx.com.Akari Therapeutics PLC Investment Alerts
| Akari Therapeutics generated a negative expected return over the last 90 days | |
| Akari Therapeutics has high historical volatility and very poor performance | |
| Akari Therapeutics may become a speculative penny stock | |
| Akari Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akari Therapeutics PLC currently holds about 8.15 M in cash with (16.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14. | |
| Akari Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio |
Akari Therapeutics PLC Upcoming and Recent Events
Earnings reports are used by Akari Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Akari Largest EPS Surprises
Earnings surprises can significantly impact Akari Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-01 | 2023-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2023-03-30 | 2022-12-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2019-11-04 | 2019-09-30 | -0.12 | -0.14 | -0.02 | 16 |
Akari Stock Institutional Investors
| Shares | Sabby Management Llc | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Omnia Family Wealth, Llc | 2024-09-30 | 87.6 K | Citadel Advisors Llc | 2024-09-30 | 33.3 K | Hpm Partners Llc | 2024-09-30 | 23.6 K | Cresset Asset Management, Llc | 2024-09-30 | 18.4 K | Renaissance Technologies Corp | 2024-09-30 | 18.1 K | Bank Of America Corp | 2024-06-30 | 150 | Advisor Group Holdings, Inc. | 2024-06-30 | 100.0 | Truvestments Capital Llc | 2024-09-30 | 50.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 8.0 |
Akari Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.35 M.Akari Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.31) | (2.42) | |
| Return On Capital Employed | 73.39 | 77.06 | |
| Return On Assets | (2.30) | (2.41) | |
| Return On Equity | 43.70 | 45.89 |
Management Efficiency
Akari Therapeutics PLC has return on total asset (ROA) of (1.7283) % which means that it has lost $1.7283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.8143) %, meaning that it created substantial loss on money invested by shareholders. Akari Therapeutics' management efficiency ratios could be used to measure how well Akari Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Akari Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 45.89 in 2024, whereas Return On Tangible Assets are likely to drop (2.42) in 2024. At this time, Akari Therapeutics' Other Current Assets are fairly stable compared to the past year. Tangible Asset Value is likely to rise to about 5.9 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.05) | (0.04) | |
| Tangible Asset Value | 5.6 M | 5.9 M | |
| Tangible Book Value Per Share | (0.05) | (0.05) | |
| Enterprise Value Over EBITDA | (0.68) | (0.71) | |
| Price Book Value Ratio | (66.68) | (63.35) | |
| Enterprise Value Multiple | (0.68) | (0.71) | |
| Price Fair Value | (66.68) | (63.35) | |
| Enterprise Value | 11.4 M | 10.9 M |
Understanding the operational decisions made by Akari Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.951 | Return On Assets (1.73) | Return On Equity (12.81) |
Technical Drivers
As of the 2nd of December, Akari Therapeutics shows the risk adjusted performance of (0.15), and Mean Deviation of 4.64. Akari Therapeutics PLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Akari Therapeutics PLC Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Akari Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Akari Therapeutics PLC. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Akari Therapeutics PLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akari Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akari Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akari Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akari Therapeutics Outstanding Bonds
Akari Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akari Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akari bonds can be classified according to their maturity, which is the date when Akari Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Akari Therapeutics Predictive Daily Indicators
Akari Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Akari Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Akari Therapeutics Forecast Models
Akari Therapeutics' time-series forecasting models are one of many Akari Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Akari Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Akari Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Akari Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Akari shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Akari Therapeutics. By using and applying Akari Stock analysis, traders can create a robust methodology for identifying Akari entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Akari Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Akari analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Akari analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 55.0 | Strong Buy | 1 | Odds |
Most Akari analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Akari stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Akari Therapeutics PLC, talking to its executives and customers, or listening to Akari conference calls.
Akari Stock Analysis Indicators
Akari Therapeutics PLC stock analysis indicators help investors evaluate how Akari Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Akari Therapeutics shares will generate the highest return on investment. By understating and applying Akari Therapeutics stock analysis, traders can identify Akari Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 13.2 M | |
| Common Stock Shares Outstanding | 4.9 M | |
| Total Stockholder Equity | -229 K | |
| Cash And Short Term Investments | 3.8 M | |
| Cash | 3.8 M | |
| Accounts Payable | 1.7 M | |
| Net Debt | -3.8 M | |
| 50 Day M A | 2.6737 | |
| Total Current Liabilities | 4.6 M | |
| Other Operating Expenses | 16.8 M | |
| Non Current Assets Total | 14 K | |
| Non Currrent Assets Other | 14 K | |
| Stock Based Compensation | 1.1 M |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.